Syndax Pharmaceuticals (SNDX) Rating Lowered to Sell at ValuEngine

Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Thursday.

Other research analysts have also issued reports about the stock. BidaskClub raised shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 24th. Morgan Stanley dropped their price objective on shares of Syndax Pharmaceuticals from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Wednesday, March 14th. Zacks Investment Research raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. TheStreet lowered shares of Syndax Pharmaceuticals from a “c-” rating to a “d” rating in a research note on Friday, April 13th. Finally, B. Riley reaffirmed a “buy” rating and set a $40.00 price objective on shares of Syndax Pharmaceuticals in a research note on Thursday, January 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $23.86.

Shares of Syndax Pharmaceuticals traded down $2.51, reaching $8.61, on Thursday, Marketbeat Ratings reports. The company’s stock had a trading volume of 1,611,800 shares, compared to its average volume of 372,388. Syndax Pharmaceuticals has a 1 year low of $11.04 and a 1 year high of $11.31. The firm has a market cap of $281.15 million, a PE ratio of -2.97 and a beta of 1.36.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, May 8th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.17. Syndax Pharmaceuticals had a negative net margin of 3,081.07% and a negative return on equity of 67.69%. The firm had revenue of $0.38 million during the quarter. research analysts anticipate that Syndax Pharmaceuticals will post -3.64 EPS for the current fiscal year.

In other Syndax Pharmaceuticals news, insider Peter Ordentlich sold 7,500 shares of Syndax Pharmaceuticals stock in a transaction on Tuesday, April 3rd. The shares were sold at an average price of $15.00, for a total transaction of $112,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 15.90% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BVF Inc. IL purchased a new position in Syndax Pharmaceuticals during the fourth quarter worth $28,326,000. BlackRock Inc. boosted its stake in shares of Syndax Pharmaceuticals by 11.0% during the first quarter. BlackRock Inc. now owns 1,276,671 shares of the company’s stock valued at $18,168,000 after purchasing an additional 126,941 shares during the period. Millennium Management LLC boosted its stake in shares of Syndax Pharmaceuticals by 18.9% during the fourth quarter. Millennium Management LLC now owns 516,500 shares of the company’s stock valued at $4,525,000 after purchasing an additional 82,256 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Syndax Pharmaceuticals by 5.3% during the first quarter. JPMorgan Chase & Co. now owns 426,941 shares of the company’s stock valued at $6,075,000 after purchasing an additional 21,581 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Syndax Pharmaceuticals by 77.7% during the first quarter. Dimensional Fund Advisors LP now owns 397,579 shares of the company’s stock valued at $5,658,000 after purchasing an additional 173,821 shares during the period. 67.11% of the stock is owned by institutional investors.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply